Sage Group plc Unsponsored ADR (SGPYY)
OTC PINK OTC PINK Primary 
The Sage Group plc (SGPYY) Q4 2025 Earnings Call Transcript
The Sage Group plc (OTCPK:SGPYY) Q4 2025 Earnings Call November 19, 2025 3:30 AM EST Company Participants Stephen Hare - CEO & Executive Director Jonathan A. Howell - CFO & Director Conference Call Participants Adam Wood - Morgan Stanley, Research Division Frederic Boulan - BofA Securities, Research Division Toby Ogg - JPMorgan Chase & Co, Research Division Charles Brennan - Jefferies LLC, Research Division Balajee Tirupati - Citigroup Inc., Research Division Presentation Stephen Hare CEO & Executive Director Good morning, and welcome to Sage's full year results.
Sage Group Launches $394 Million Buyback After Profit, Revenue Rise
The software company outlined a buyback program of up to $394 million after it reported higher pretax profit and revenue, boosted by growth in key markets.
BigBear.ai Stock Stays Hot After Earnings, Ask Sage Purchase
BigBear.ai Holdings (NYSE:BBAI) is one of the better stocks on Wall Street today, last seen up 13.8% to trade at $6.90.
BigBear.ai's Ask Sage Buyout: Can it Become a GenAI Powerhouse?
BBAI's $250M Ask Sage deal could reshape its AI role in defense, with platform growth and secure model deployment at the core.
BigBear.ai Q3: What The Ask Sage Acquisition Means For Investors
BigBear.ai reports Q3 revenue down 20% but announces a $250 M Ask Sage AI-wrapper acquisition targeting government clients. A $376 M backlog highlights steady demand; Ask Sage could offset revenue decline and expand secure multi-LLM government integrations. A cash balance of $456.6 M enables deal closure, though dilution risk remains as operations stay unprofitable.
Sage Group (SGPYY) Upgraded to Strong Buy: Here's What You Should Know
Sage Group (SGPYY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The Sage Group plc (SGGEF) Presents at Sales/Trading Statement Conference Transcript
The Sage Group plc (OTCPK:SGGEF) Sales/Trading Statement Conference Call July 30, 2025 3:30 AM ET Company Participants Jonathan Anton George Howell - CFO & Director Conference Call Participants Adam Dennis Wood - Morgan Stanley, Research Division Frederic Emile Alfred Boulan - BofA Securities, Research Division Johannes Schaller - Deutsche Bank AG, Research Division Kai Folker Korschelt - Canaccord Genuity Corp., Research Division Toby Ogg - JPMorgan Chase & Co, Research Division Operator Good morning, everyone. Welcome to the Q3 Trading Update Call for The Sage Group.
Sage Group: Slow burner, no fireworks, says leading investment bank
JP Morgan's preview of The Sage Group PLC (LSE:SGE) third-quarter figures suggests there won't be fireworks when the software group reports on July 30. Analysts there reckon the company will deliver roughly the same 9% year-on-year organic growth it achieved in the first half of its financial year, neither better nor worse.
All You Need to Know About Sage Group (SGPYY) Rating Upgrade to Strong Buy
Sage Group (SGPYY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Sage Group plc (SGGEF) Q2 2025 Earnings Call Transcript
The Sage Group plc (OTCPK:SGGEF) Q2 2025 Earnings Call Transcript May 15, 2025 3:30 AM ET Company Participants Steve Hare - Chief Executive Officer Jonathan Howell - Chief Financial Officer Conference Call Participants Frederic Boulan - Bank of America Adam Wood - Morgan Stanley Kai Korschelt - Canaccord Genuity Balajee Tirupati - Citi Sven Merkt - Barclays Steve Hare Good morning and welcome to Sage's results for the First Half of the Year. I'm pleased to be joined by Jonathan Howell, our CFO.
Sage Group slips despite profits beat and buyback extension
The Sage Group PLC (LSE:SGE) shares fell 4.5% on Thursday morning after the accountancy software group published half-year results that seemed to be in-line or ahead of City forecasts. An existing share buyback was increased to £400 million from £200 million.
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y
SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.
